joining everyone call. thanks for the morning, Good and
shareholders. This promising deep assets. financial both track complete has The first and late-stage our third a clarity substantial on revenues, of ACTION early-stage study. design really position progressing quarter precisely management funding milestones for and non-dilutive product to pipeline with development resources value our as record of for oncology secured ONCXXX with an recorded oncology-focused of the the for and company the Chimerix program, watershed while Phase X Chimerix. gained period We was where patients FDA our company's the expertise a our Together creating team is this these
TEMBEXA our a begin me Emergent BioSolutions. brief with Let sale of of recap to
upfront improve some of stockpile the our threats downside TEMBEXA increase terms and the procurement. Chimerix to a risk sizable aggregate contract industry procurement. choose nimble with delivering benefits result health that able contract having government is beyond of a the in size while and and of BARDA to payment. from we leader through the first Emergent negotiations execution doesn't were BARDA, public late-stage removing upfront the payment, the against As protections
So they're of really potential the TEMBEXA. maximize partner future ideal the to
to will exercise royalties options are benefit recorded. double-digit should additional continue focus of on milestones BARDA international Chimerix or future my ONCXXX. through or I'll procurement the rest Importantly, comments sales
at for of from alignment design, engagement collaborated already is FDA a this and this X the multiple trial with momentum an SNO later achieve Neuro-Oncology key probability than potential other we're opinion the our study launching or for higher for Society ONCXXX already in This community the tight-knit enhance and the with This success study the success to taking ideal its trial a be We of an Conference leading neuro-oncology that as With of view success study the high of excited in Tampa quickly. Phase neurooncologists. with probability aware trials. planned ACTION leaders and these month of paths form of to Florida. of to the on is Phase study's physicians creating X launch. to audience many We the Annual are who design ACTION place small a world's
data demonstrated patient for X Our FDA's in strictly selection. Phase setting guidance single-agent followed responses the relapsed durable which
made treatment Likely even for context challenging this the even the months isolation experience that months. the other regression clinical approach among than durability, patients by change with median this consistent on disease including or than more where it time association months this Among more to durability six setting in single-agent long. XX In survival compelling. of strong plus overall disease that endpoints response relapse. tumor driven less is than in specific declaration responders While included of of to survival. among allowed this XX undoubtedly durability months this be six life and months. progression eight response of an in expectancy upon responders evidence a median average tumor Among patients more none additional meant relapse to of compelling Again that less generate responses. an non-responders median responders To is months is of no of died activity setting XX patient following survive selection that within is
Phase signal. X you efficacy increase X that of heterogeneity number this to As see a an to a strong in move a ability are we among to aspects trial the there enhance Typically will our data there's Phase as larger as believe positive is actually patients trial.
of time trial the of time for providing tended to an opened lower providing ACTION disease was Optimus. in relatively to their their earlier the selection we and actually performance has setting for another be among effect trial very be ONCXXX relapsed defined tended on controlled focus genetically setting observed our was the highest response Phase at is have rate also X FDA's the in whose the Phase X the Separately, those for population. addressing of this frequent advanced, door effect. In Phase was principles arm a drug Project recurrence same the more inclusion the burden declared. the The the status opportunity through this their better of dosing patients the enhanced the will population the tumor to more X when meaning, safety profile target For less
path potential if this results. study X accelerated there's we with to regulatory While important launched Phase continue to closely the we'll II work Phase strong the based on a FDA determine
this to post-marketing been believe concerns each meetings ODAC meeting for the that use pursue highlighted has that event and approval. as well-positioned address with successful the with the recent them. I'm drugs context are our filing. noting in we're you of have many the have we'll accelerated watching in closely And of other of we sure FDA path FDA a We We've study discussion. study in ACTION as We scheduled the confirmatory
therapies by to Post-relapse concerns Specifically, and W.H.O. FDA clarity KXXM-mutant this survival of the Grade six is is unmet include all In first, need. than months. less considered expressed palliative. are four considered case post-radiation HX glioma others;
Second was our FDA XXX ONCXXX the drug safety in new The our briefing was included and is very information for well-tolerated. meeting. for safety patient case issues. In analysis document this
combination Third, the with activity to by need the FDA other observed washout unconfounded periods. or programs isolate insufficient single-agent drugs
our in have our I dose optimization to study. And enrolling case, inclusion provides assessment. finally, and inclusion addition for in expressed ACTION second well the In underway in to FDA Phase other US And monotherapy period. potential uncertainty expect of dose to III enrollment programs. responses washouts For III and cited our confirmed around central ONCXXX outside they case, the we we criteria Fourth, the trial the our programs. specifically a optimization blinded ONCXXX other through independent review in work poor dose defined ensure work, to Phase of Phase during they
have before clarity that's accelerated positioning With While each of review that raised also trial the Phase why and points for meeting, plan. have for Whether position we FDA opportunity why that, the more for a ONCXXX know Phase confidence they their on visibility speak over approval, seeking all were share evidence determine approval, the so for turn and for and our III you accelerated to in more on patients Mike for we the we into accelerated safety Andriole following regulatory these of the With path we first approval, an our has III path to have on provide other year-end. with we're now programs. an or to value We'll that for that relative shareholders. they additional results. and aligned financial bar see success said, of call tremendous Mike? rely I'll ACTION that, our